IN COLLABORATION WITH JAPANESE AND SINGAPOREAN PARTNERS, SILO STRENGTHENS CANCER SPECIALTY SERVICES

Jakarta, February 23, 2023 – PT Siloam International Hospitals Tbk. (SILO), a subsidiary of PT Lippo Karawaci Tbk.(LPKR) in the healthcare sector, is committed to advancing the healthcare industry by enhancing specialized medical services through its Centers of Excellence (CoE) programs, particularly in cancer care. To achieve this, SILO has established partnerships with international institutions through the Mochtar Riady Comprehensive Cancer Center (MRCCC), including the National Center for Global Health and Medicine (NCGM) from Japan and SingHealth from Singapore. These collaborations aim to improve cancer treatment, conduct clinical trials, enhance medical talent through Good Clinical Practice (GCP) training, and provide on-site training.

Going forward, SILO will continue to invest in its medical capabilities by procuring 10 new Linear Accelerators (Linacs) to meet the growing demand for radiotherapy services outside Jakarta and Java Island. These initiatives are part of SILO’s commitment to improving cancer prognosis while delivering personalized and precise care for every patient.

As part of the SILO network, the Mochtar Riady Comprehensive Cancer Center (MRCCC) upholds the vision of becoming a “Building of Hope” for all cancer patients. Since opening in 2011, MRCCC has remained the only accredited private cancer center in Indonesia and has evolved into a trusted tertiary referral center for hospitals and clinics nationwide. SILO continues to play an active role in narrowing the cancer care gap by collaborating with the government, health organizations, strategic partners, and local communities.

At MRCCC, early detection, surgical oncology, chemotherapy, and radiotherapy services are all provided under one roof. By 2022, MRCCC had served over 91,000 cancer patients, delivered more than 34,000 radiotherapy sessions, 10,000 chemotherapy treatments, conducted over 4,600 PET-CT scans, and performed more than 2,900 surgical procedures. MRCCC is equipped with a wide range of diagnostic tools and facilities, including ultrasound, mammography, MRI, PET-CT scans, as well as molecular diagnostics laboratories and immunohistochemistry pathology labs to support accurate diagnoses and treatment planning.

Moreover, MRCCC provides various cancer treatment modalities, including surgery, chemotherapy, radiotherapy, and customized therapies such as targeted therapy and immunotherapy, tailored to the individual’s genetic profile. Future cancer treatment at MRCCC will increasingly adopt a personalized approach based on each patient’s cancer type and genetic mutations.

John Riady, Group CEO of LPKR and President Commissioner of SILO, stated that SILO acknowledges certain medical conditions require specialized care. “SILO offers Centers of Excellence staffed with expert specialists and dedicated facilities to address the unique needs of patients and deliver comprehensive care. Our CoEs provide targeted services that support patients with specialized health needs,” he explained.

John also reiterated LPKR’s commitment through SILO to the ongoing development of the healthcare industry in Indonesia. “Healthcare is a critical sector that must be developed in Indonesia. As the economy continues to grow, the demand for quality healthcare facilities will increase. LPKR, through SILO, will continue expanding our clinical capabilities. Our mission is to meet Indonesia’s healthcare needs, and we remain committed to sustainable growth,” John affirmed.